News

Name: Cordis
Price range: $

Jul 16, 2024

Cordis Awarded Vascular Closure Devices Agreement with Premier, Inc. for MYNX CONTROL™ VENOUS Vascular Closure Device

Jul 9, 2024

Cordis receives FDA approval for MYNX CONTROL™ VENOUS Vascular Closure Device

MYNX CONTROL^™ VENOUS Vascular Closure Device now brings the proven technology of the MYNX^™ Family of Products to mid-bore venous puncture sites, including electrophysiology procedures.

Jun 18, 2024

Cordis Announces Positive 24-Month Results from the SELUTION Superficial Femoral Artery (SFA) Japan Study

Nov 16, 2023

Cordis Announces Enrollment Completion of the RADIANCY Clinical Study in Europe

Nov 6, 2023

Cordis Announces Scott Drake as Chief Executive Officer

Oct 31, 2023

World's First Patient Enrolled in SELUTION4DeNovo DEB IDE Trial

Oct 24, 2023

Patient enrollment in SELUTION SLR™ DEB SUCCESS PTA Study

Cordis announces the completion of patient enrollment in SELUTION SLR^™ DEB SUCCESS PTA Study

Oct 16, 2023

Cordis issues statement on the CMS announcement to expand coverage of carotid stenting

Oct 2, 2023